drugset / Trial / NCT00037830
GM1 Ganglioside Effects on Parkinson's Disease
Phase 2
Completed
94 enrolled
Thomas Jefferson University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this trial is to examine the short term effects (24 Weeks) of GM1 on Parkinson's disease (PD) symptoms, as well as the effects of long-term treatment (120 Weeks) with GM1 on disease progression, and to examine the extent to which GM1 treatment influences the underlying disease process in PD.
Timeline
- Start
- 1999-11
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GM1 ganglioside | Unknown | 100 mg | Subcutaneous |